IL1B and diabetic cardiomyopathy: Studies unveiled that inhibiting p38MAPK activity in diabetic cardiomyopathy mouse models effectively lowers the levels of inflammatory cytokines such as TNF-α, IL6, IL1-β, and TGF-β1 in myocardial tissue, thus improving the left ventricular function of DCM mice [33].